Key Points This study is the first to assess the prognostic value of FVIII-specific antibody data in patients with AHA. Anti-FVIII IgA, but not immunoglobulin G, autoantibodies at baseline are potential predictors of recurrence and poor outcome of AHA.
Intergroup conflict contributes to human discrimination and violence, but persists because individuals make costly contributions to their group's fighting capacity. Yet how group members effectively coordinate their contributions during intergroup conflict remains poorly understood. Here we examine the role of oxytocin for (the coordination of) contributions to group attack or defense in multi-round, real-time feedback intergroup contests. In a double-blind placebo-controlled study with N=480 males in Intergroup Attacker-Defender Contests, we found that oxytocin reduced contributions to attack and over time increased attacker's within-group coordination of contributions. However, rather than becoming peaceful, attackers given oxytocin better tracked their rival's historical defense and coordinated their contributions into well-timed and hence more profitable attacks. Our results reveal coordination of contributions as a critical component of successful attacks and subscribe to the possibility that oxytocin enables individuals to contribute to in-group efficiency and prosperity even when doing so implies outsiders are excluded or harmed.
In a randomized open study, the combination of either prostaglandin El (PGE,) or pentoxifylline with controlled vascular training was compared with vascular training alone in patients with peripheral arterial occlusive disease in stage IIb. Forty-four patients were randomly assigned to treatment either of intensive vascular training alone (n=15) or in combination with either IV pentoxifylline (200 mg over 2 hours BID, n= 15) or PGE, (40 gg over 2 hours BID, n= 14). The basic therapy was a well-defined routine for vascular training, which was identical for all groups. The duration of therapy was 4 weeks. In all three test groups, there was a significant increase in the walking distance. There was a 119% increase in symptom-free walking distance in the exercise-only group. In comparison with exercise alone, the additional administration of pentoxifylline produced no greater effect; the increase was 105%. In contrast, administration of PGE, combined with exercise achieved a remarkable improvement of 604%. Between-group comparison revealed the significant superiority of treatment with PGE1 (P<.05). During the 1-year follow-up, there was a reduction in the walking performance in all groups, albeit of variable extent. In the exercise-only and the pentoxifylline groups, the maintained increase in walking distance was only 30% compared with baseline values before the beginning of therapy. In the PGE1 group, on the other hand, the maintained improvement was 149%. Nine of 14 patients were still in stage IIa of peripheral arterial occlusive disease 1 year after PGE1 therapy. (Circulation. 1994;90(818-822.) Key MethodsA total of 44 patients (33 men and 11 women) with stage lIb PAOD (age range, 42 to 81 years; mean, 60±9 years) were included in a randomized open trial. Mean body weight was 74±14 kg, and mean height was 168±9 cm. Mean blood pressure was 156/88±21/11 mm Hg, and heart rate averaged 75±9 beats per minute.Included in the study were patients with PAOD of the lower extremities who were stable and in stage IIb of the disease, according to Fontaine's classification.Further requirements were that the arterial occlusive disease had existed in this stage for more than 6 months and that it had been confirmed by intra-arterial digital subtraction angiography or conventional angiography that the stenosis or occlusion was of the upper leg or lower leg type. Maximum walking distance on the treadmill up a 5% slope at a walking pace of 3 km/h had to be at least 50 m and no more than 200 m. In addition, each patient's informed consent was required. Exclusion criteria were defined as pregnancy, decompensated heart failure, decompensated renal failure, hemodynamically relevant aortic or iliac arterial occlusion, presence of necrosis or pain at rest, respiratory insufficiency, joint problems affecting walking distance, myocardial infarction within the past 6 months, indispensable therapy with vasoactive drugs or drugs affecting peripheral perfusion, tendency to hypotonic collapse or orthostatic dysregulation (postural ...
Dose finding of LIPO-PGE1: After bolus injection of 30, 50, and 80 micrograms LIPO-PGE1 a significant dose-dependent increase of the blood flow in the leg (+96.9%, 80 micrograms) with a peak 3 h after injection was seen. After LIPO-PGE1 we observed an enhanced microcirculation (significant rise in the transcutaneous oxygen pressure and the skin temperature on the foot). We noted longer lasting pharmacodynamic properties with LIPO-PGE1 (50 micrograms) compared to PGE1-cyclodextrin (60 micrograms). Comparison to PGE1-cyclodextrin: In a cross-over, placebo-controlled study, 20 patients with intermittent claudication received 4 weeks therapy with a bolus of 50 micrograms LIPO-PGE1 or a 2 h infusion of 60 micrograms PGE1-cyclodextrin per day. A significant increase in the blood flow was measured at the end of 4 weeks therapy compared to the initial values before treatment. This rise correlates significantly with the increase in the patient's maximal walking distance (+112%, LIPO-PGE1). Compared to conventional PGE1-cyclodextrin infusions given over 2 h, a clearly prolonged increase in perfusion of the affected limb after LIPO-PGE1 was demonstrated. No serious adverse effects were observed.
The extracellular adherence protein (Eap) from Staphylococcus aureus has been suggested as a vaccine candidate and for therapeutic use due to its immunomodulating and antiangiogenic properties; however, little is known about anti-Eap antibodies in humans. We determined anti-Eap antibody titers by enzyme-linked immunosorbent assay and Western blot and measured serum samples from 92 patients with proven S. aureus infections and 93 healthy controls. The functionality of antibodies was assessed by a phagocytosis assay using Eap-coated fluorescent microspheres. Antibodies were detected in all human samples, but not in mice. Patients showed significantly higher titers than controls [immunoglobulin M (IgM), P=0.007; IgG, P<0.0001]. Patients with deep or severe infections showed higher titers than those with superficial or mild disease. Eap alone was sufficient to promote phagocytosis by peripheral blood mononuclear cell and granulocytes that was moderately enhanced in the presence of human serum, but no correlation was found with the levels of anti-Eap antibodies. Anti-Eap antibodies are prevalent in all tested humans and correlate with the severity of S. aureus infection; however, they do not seem to provide protection against invasive infections. Before considering Eap for therapy or as a vaccine candidate, further studies are warranted to assess the impact of the interference between Eap and its specific antibodies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.